Zymeworks Inc. announced Dr. Jeffrey Smith has been promoted to Executive Vice President and Chief Medical Officer, where he will play a key role in leading the clinical development of early-stage programs and overseeing integrated global early-stage development group. Dr. John Fann has been promoted to Senior Vice President, Process Sciences, where he will continue to play a key role in supporting the advancement of new product candidates from preclinical studies into clinical trials.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.04 USD | -0.77% |
|
-0.33% | -12.99% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.99% | 644M | |
+18.15% | 124B | |
+18.02% | 112B | |
+4.43% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-15.87% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ZYME Stock
- News Zymeworks Inc.
- Zymeworks Inc Announces Additional Leadership Appointments